CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Ocular Therapeutix, Inc. (OCUL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Ocular Therapeutix, Inc. (OCUL)

Pharmaceutical Preparations · market cap $2.2B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-01-08 (est.)
Phase 3
Pipeline
16
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Ocular Therapeutix (OCUL) is a 274-employee ophthalmology-focused pharma company with a ~$1.42B market cap and $598.6M in cash. Its lead asset is OTX-TKI, an axitinib implant, in Phase 3 for neovascular AMD, and it also has Phase 3 work in non-proliferative diabetic retinopathy plus a long list of earlier and legacy ocular programs. Our calendar shows a cluster of high-importance events between January and June 2027, all with estimated dates.
The catalyst path
  • 2027-01-08 (est.)Phase 3 · OTX-TKIimp 9/10
  • 2027-03-15 (est.)Phase 3 · Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24imp 9/10
  • 2027-06-12 (est.)PDUFA · Axpaxliimp 8/10
Pipeline
AssetPhaseIndication
OTX-TKI (axitinib implant)Phase 3Neovascular Age-Related Macular Degeneration
OTX-TPPhase 2Glaucoma
Punctum PlugPhase 3Post Ocular Surgical Inflammation and Pain
OTX-CSIPhase 2Dry Eye Disease
OTX-DEDPhase 2Dry Eye
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24Phase 3Non-Proliferative Diabetic Retinopathy
Ophthalmic InsertPhase 3Open Angle Glaucoma and Ocular Hypertension
OTX-TIC low dose Travoprost Intracameral ImplantPhase 2Open Angle Glaucoma
Dextenza Ophthalmic InsertPhase 3Cataract
TravoprostPhase 3Open Angle Glaucoma
OTX-DP (Dexamethasone punctum plug)Phase 2Ocular Inflammation and Pain
Controlled InsertionPhase 2Dry Eye Syndromes
DexamethasonePhase 3Allergic Conjunctivitis
OTX-TKIPhase 3Neovascular Age-related Macular Degeneration
OTX-TIC high dose Travoprost Intracameral ImplantPhase 2Open Angle Glaucoma
Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24Phase 3Non-Proliferative Diabetic Retinopathy
Price & technical context
3-month
-45.0%
6-month
-27.8%
12-month
-45.9%
52-wk range
$6.05–$16.11
vs 50-day MA
-23.4%
vs 200-day MA
-31.9%
Realized vol
75.4%
Max drawdown
-62.4%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for OCUL (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.